Learn More
BACKGROUND GP2015 is a proposed etanercept biosimilar. OBJECTIVES To demonstrate equivalent efficacy, and comparable safety and immunogenicity of GP2015 and the etanercept originator (ETN, Enbrel®(More)
BACKGROUND EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque-type psoriasis as a part of totality of evidence gathered during the development of GP2015,(More)
  • 1